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THE EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION ON 
DUAL-TASK WALKING IN PARKINSON’S DISEASE 
VICTORIA NGUYEN  
ABSTRACT  
Background: Parkinson’s disease (PD) is a common debilitating disorder that largely 
effects the aging population. It is associated with a loss of dopamine-producing brain 
cells, which leads to abnormal brain activity and ultimately, a loss of locomotor control. 
Transcranial direct current stimulation (tDCS) is a technology that effectively modulates 
brain excitability by sending low electric current through the scalp. It has been 
demonstrated to improve working memory, intelligence, learning ability, as well as 
relieving symptoms of depression, Alzheimer’s and schizophrenia (Kekic, Boysen, 
Campbell, & Schmidt, 2015; Khedr et al., 2014; Manor et al., 2015). tDCS may thus 
serve as an effective therapeutic strategy for this vulnerable PD population. 
 
Objective: The primary purpose of this study was to examine the acute effects of single 
sessions of tDCS targeting different brain networks on locomotor control metrics and 
other outcomes in patients with PD. 
 
Design: A pilot, double-blinded, sham-controlled study.  
 
Methods: A total of 15 older adults between the ages of 40-85 with a physician diagnosis 
of PD will be recruited. Participants are screened with questionnaires to determine 
		 vii 
eligibility. If eligible, participants will undergo a dual task assessment and a freezing of 
gait (FOG) provoking protocol prior to, as well as immediately after, a 20-minute session 
of tDCS. The acute effects of each stimulation session will be observed. There will be 
three different stimulation conditions that each target different areas of the brain: the 
motor cortex (M1), the motor cortex and the dorsolateral prefrontal cortex (DLPFC), and 
a sham (i.e., control) condition. Multiple aspects of locomotion (i.e., FOG, gait speed, 
stride time variability, percent of each walking stride spent with both feet on the ground) 
and cognition are assessed.  
 
Results: This study began enrolling participants on March 3rd, 2016. To date, one 
participant has been enrolled and completed baseline testing as well as all three tDCS 
visits. This 42-year-old participant was diagnosed with PD two years ago and symptoms 
are mild. No side effects were observed during tDCS and the participant was unable to 
decipher between the M1 and the sham stimulation, but was able to tell the difference 
between sessions when receiving multi-focal stimulation.  
 
Discussion: In this case study, tDCS was well tolerated by the patient and double-
blinding procedures were effective. Thus, while tDCS did not induce significant 
improvements in gait or cognition in this relatively high functioning patient, the 
developed study protocol and tDCS intervention are highly feasible in the PD population. 
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INTRODUCTION 
 Parkinson’s disease (PD) is the second most common dementing 
neurodegenerative conditions following Alzheimer’s disease (Mollenhauer et al., 2010). 
According to the National Institute of Neurology Disorders and Stroke, approximately 
500,000 people suffer from PD in the United States alone. PD affects people worldwide 
and with the increasing average life expectancy rising in developed countries, this 
number is expected to grow. A resting tremor of a limb is typically the initial symptom 
and overtime it increases in severity with the addition of other debilitating symptoms 
such as bradykinesia, rigidity and freezing of gait (FOG) (Morris,	2000). These 
symptoms are attributable to the degeneration of dopaminergic neurons of the substantia 
nigra that feed into the motor striatum (Mendez et al., 2005). The presence of lewy bodies, 
an abnormal aggregation of proteins, and nerve cell loss in the substantia nigra are 
defining features present in those with Parkinson’s disease. An exact cause of PD has not 
yet been discovered; however, its pathogenesis likely stems from a plethora of factors 
including genetics, environmental stimuli, oxidative stress, and mitochondrial 
dysfunction (Mizuno et al., 1998). 
Parkinson’s disease (PD) is a neurodegenerative disorder classically recognized as 
a constellation of motor symptoms including locomotor instability. Cognitive function is 
also affected; however, and together with motor symptoms, worsens with time (Breen & 
Drutyte, 2013). Executive dysfunction includes progressive difficulty with selective and 
sustained attention, planning, and inhibitory control and dual tasking (Dirnberger & 
Jahanshahi, 2013). Together, motor and cognitive impairments diminish quality of life 
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and psychiatric comorbidities such as depression typically appear (Schrag, Hovris, 
Morley, Quinn, & Jahanshahi, 2006).  
The increased prevalence of neurodegenerative diseases like Parkinson’s disease 
brings attention to the necessity of catering to our aging population  (Wright Willis, 
Evanoff, Lian, Criswell, & Racette, 2010).  Unfortunately, the wide range of PD-related 
symptoms and associated clinical manifestations has made it difficult to develop 
treatments that cater to the specific needs of each individual patient. Dopamine therapy is 
a common treatment; however, its efficacy diminishes with the progression of the disease 
as it spreads further past the dopaminergic neuronal systems (Gerlach et al., 2002). PD 
can be thought of as a syndrome of interacting dysfunctions from a variety of neural 
networks that influence a wide range of cognitive and motor functions (Gratwicke, 
Jahanshahi, & Foltynie, 2015). Surgical interventions such as deep brain stimulation have 
become an option of treatment but risk serious complications. Recently, non-invasive 
brain stimulation, including both transcranial magnetic stimulation (TMS) and 
transcranial direct current stimulation (tDCS), has shown early promise an effective 
therapy for multiple PD symptoms.   
tDCS is safe, user-friendly and cost efficient.  It has therefore recently gained 
popularity as a research and clinical tool (Nitsche & Paulus, 2000). tDCS works by 
sending weak (≤ 2.0 mA) electrical currents between two or more sponge or gel 
electrodes placed upon the scalp. This current alters brain polarization and thus, increases 
or decreases neuronal membrane excitability (Liebetanz, Nitsche, Tergau, & Paulus, 
2002). A single 20-minute “dose” of tDCS does not directly induce neuronal firing, but 
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instead alters neuronal excitability (i.e., the likelihood of firing) for up to four hours 
following administration. Moreover, the brain networks influenced by tDCS are 
dependent upon electrode placement. As such, electrode configuration can be 
manipulated to target different brain networks and as such, may eventually enable 
researchers and clinicians to selectively target specific networks on a patient-to-patient 
basis (Brunoni et al., 2012). 
PD is not only associated with altered function of the basal ganglia (located deep 
within the brain), but also with reduced excitability of numerous “higher-level” brain 
regions, including the motor cortex and the dorsolateral prefrontal cortex (Pascual-Leone 
et al., 1994). Previous studies have shown that a single stimulation session over the 
primary motor cortex (M1) significantly improved the execution of particular tests such 
accuracy in arm tracing, shaping tasks like buttoning a shirt or pouring water, and knee-
extension force in post-stroke patients (Matsuo et al., 2011; Tanaka, 2015; Williams, 
Pascual-Leone, & Fregni, 2010). A single stimulation session targeting the DLPFC has 
also demonstrated promising results in those affected by depression. Specifically, 
modulating the excitability of this brain region helped alleviate major depressive 
symptoms by averting attention away from emotional stimuli and improving accuracy on 
a working memory test and a Go-NoGo inhibition task testing simple reaction time 
(Boggio et al., 2007; Wolkenstein & Plewnia, 2013).  
Dual Tasking 
Dual task walking refers to the ability to walk while concurrently talking, reading 
or thinking, and is thus of critical importance to the safe completion of most activities of 
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daily living. Without the ability to properly attend to both tasks, the elderly may put 
themselves at risk of falling (Beauchet, Dubost, Gonthier, & Kressig, 2005; Lundin-
Olsson, Nyberg, & Gustafson, 1997). The ability to maintain stable locomotor control, 
especially when dual tasking, is dependent upon one’s ability to activate the appropriate 
motor and cognitive networks within the brain (Salo, Rinne, Salonen, & Alho, 2015).  
These regions include both the M1 and DLPFC regions, which are both functionally and 
anatomically linked to the basal ganglia (Galvan, Devergnas, & Wichmann, 2015). As 
such, dual task capacity is often significantly reduced in patients with PD as compared to 
their age-matched counterparts (Fernandes et al., 2015). 
 There are various mechanisms that may serve as an explanation as to why 
performance suffers in dual-tasking. Specifically, dual task deficits may arise due to a 
lack in the ability to switch one’s attention between each task or a generally limited 
attentional capacity. A motor deficit may be due to an increased demand over postural 
control for limited attentional resources (Hall, Echt, Wolf, & Rogers, 2011). There are 3 
common theories: 
Theory Explanation 
The capacity-sharing theory Two tasks demanding attention will cause one 
of them to deteriorate. 
The bottleneck theory Processing of multiple tasks will cause a delay 
as the one task gets processed at a time.  
Table 1: Theories of dual task performance decline. There are three leading 
theories to explain why people are limited in performing multiple tasks at the same 
time (Yogev, Hausdorff, & Giladi, 2008). 
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The multiple resource models theory Multiple tasks share common resources and 
cause an uneven distribution. 
 
As such, strategies designed to enhance of excitability of the M1 and DLPFC regions, 
such as tDCS, may be particularly well suited for the improvement of dual task walking 
and other motor and cognitive outcomes in PD.  
Freezing-of-gait (FOG) 
Balance impairment is a key symptom in the progression of PD. Bradykinesia, 
rigidity, impaired proprioception, and freezing of gait (FOG) contribute to the increased 
risk of falls in those with PD (Park, Kang, & Horak, 2015). In particular, approximately 
70% of those suffering with PD will specifically develop FOG (Heremans, Nieuwboer, & 
Vercruysse, 2013; Maidan et al., 2015). Giladi and Nieuwboer define FOG as “an 
episodic inability (lasting seconds) to generate effective stepping in the absence of any 
known cause other than Parkinsonism. It is most commonly experienced during turning 
and or step initiation, but may also occur when the patient is faced with spatial constraints, 
stress, or distractions. Patients have described this sensation as having their feet “glued to 
the floor” and can often be observed as a shuffling motion as they attempt to initiate 
movement.  
The pathophysiology of FOG is poorly understood and finding a treatment that 
best suits a particular patient’s case is challenging. Dopamine treatments such as the 
long-term use of Levodopa may control certain PD symptoms, but may actually worsen 
FOG symptoms (Ambani & Woert, 1973; Vorovenci, Biundo, & Antonini, 2015). 
Focused attention and/or external stimuli (cues), including the use of devices such as the 
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modified inverted stick and a visual laser beam stick, may assist in overcoming an 
episode (Giladi & Nieuwboer, 2008).”  These devices, however, have not shown to be 
consistently beneficial and FOG is still considered an untreatable clinical symptom 
(Kompoliti, Goetz, Leurgans, Morrissey, & Siegel, 2000). Although new methods are 
being researched and some have demonstrated promise (e.g., deep brain stimulation or 
intrajejunal infusion of levodopa-carbidopa intestinal gel through the insertion of a 
gastrojejunostomy tube), research has been largely limited to case studies and may 
involve invasive procedures (Cossu et al., 2015; Niu et al., 2012).  
 
Figure 1. Progression of PD on postural instability – Overtime symptoms such as 
bradykinesia and rigidity worsen as new debilitating symptoms like freezing begin. 
Figure taken from (Park et al., 2015). 
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Rationale and Objectives  
The control over one’s balance is dependent on various brain processes that 
communicate with the peripheral neuromuscular system to integrate and utilize sensory 
feedback during both dynamic and static balance conditions (Takakusaki, Habaguchi, 
Ohtinata-Sugimoto, Saitoh, & Sakamoto, 2003). The coordination of locomotion is 
particularly reliant upon the involvement of the basal ganglia to regulate muscle tone and 
adapt postural response patterns to ever-changing environmental and task conditions 
(Horak, Dimitrova, & Nutt, 2005).  
In 2006, Fregni and colleagues examined the effects of tDCS targeting the 
primary motor cortex (M1) on motor function in PD participants.  In comparison to sham 
stimulation (i.e., placebo), 20 minutes of real tDCS induced acute enhancement of simple 
reaction time and the motor sub-score of the Unified Parkinson’s Disease rating scale 
(UPDRS) (Fregni et al., 2006). Benninger and colleagues (2010) also reported motor 
improvements in terms of walking speed in PD patients receiving real tDCS, as compared 
to receiving sham stimulation.  In this particular study, eight sessions of tDCS were given 
over multiple days, and the target for stimulation was alternated between M1 and the 
dorsolateral prefrontal cortex (DLPFC). This intervention was associated with both 
immediate and longer-term improvements in locomotor control (Benninger et al., 2010).    
Most recently, Manor, Zhou and colleagues (2014, 2015) demonstrated that  
a single 20-minute session of real tDCS targeting the DLPFC, as compared to 
sham, significantly reduced the dual task cost to walking speed and stability in 
both younger and older healthy adults (Manor et al., 2015; Zhou et al., 2014). Studies 
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have also shown that dual-tasking can trigger short-term movement cessations in those 
who suffer from FOG (Giladi & Nieuwboer, 2008; Spildooren et al., 2010). Thus, by 
targeting cortical networks that are involved in the control of dual-tasking, tDCS may 
additionally alleviate FOG symptoms.   
Together, these recent studies provide preliminary evidence that tDCS targeting 
the M1 or DLPFC may improve locomotor control in PD. Moreover, recent 
advancements in the modeling of tDCS current flow have enabled researchers with the 
ability to simultaneously target multiple regions of the brain (Ruffini, Fox, Ripolles, 
Miranda, & Pascual-Leone, 2014). We contend, therefore, that simultaneous stimulation 
of cognitive and motor networks will improve locomotor control, especially when dual 
tasking, and reduce FOG, in patients with PD.  The effects of such "multi-focal" tDCS on 
these outcomes in patients with PD, however, have not been established.  
The aim of this study is to examine the acute effects of single sessions of tDCS 
targeting different brain networks on locomotor control metrics and other outcomes in 
patients with PD. We hypothesize that tDCS simultaneously targeting the DLPFC and 
M1 cortex will reduce the dual task cost to gait speed, the number of FOG episodes, more 
so than tDCS targeting the M1 region alone or sham stimulation. 
 
Application and importance  
PD is associated with often debilitating motor and cognitive impairments, locomotor 
disturbances such as FOG, and falls. The pathophysiology of FOG is still not fully 
understood but has been associated with gait pattern generation disturbances in those with 
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PD (Heremans et al., 2013). This study will provide valuable preliminary data on the 
potential for tDCS to be used as a therapy for PD and its various debilitating symptoms. 
Specifically, this research will demonstrate the effects of noninvasive brain stimulation 
on the ability of patients with PD to walk with and without performance of additional 
cognitive tasks. It will therefore serve as grounds for further investigation into the use of 
tDCS to provide symptomatic relief within the vulnerable population. 
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METHODS  
Study cohort 
 
This study will be achieved with the participation of senior citizens recruited from 
the Boston area through newspaper ads (The Metro and The Herald) as well as through 
recruitment at Hebrew Senior Life affiliated senior-living facilities (Orchard Cove and 
NewBridge). Study inclusion criteria are ages 40-85 years, a physician-diagnosis of 
idiopathic PD, a stable medication regimen (i.e., no change in medications within 1 
month of the study, with no plans of changes medications during the study), and mild-to-
moderate severity of PD-related symptoms as determined by:  
A) a Hoehn and Yahr (H&Y)  score of 1-3.5, and  
B) freezing of gait (FOG) identified by the validated "New FOG" questionnaire 
with a score of 9 or above. 
Exclusion criteria includes any self-reported cardiovascular, neurological, or 
musculoskeletal disorder not related to PD, current use of any centrally acting medication, 
recent hospitalization, an inability to read, write, or communicate in English, an Mini 
Mental State Examination (MMSE) score less than 22, and any other condition resulting 
in abnormal physical function. 
 
Study Protocol 
Phone screen  
Study personnel screen subjects over the phone in order to determine if they 
qualify for an in-person screening. Questions are asked regarding overall health, PD 
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diagnosis, and FOG episodes (if applicable). The FOG symptom is assessed using a 10 
question “freezing-of-gait” questionnaire (NFOGQ) to determine frequency and severity. 
 
Visit 1 (V1): Screening and baseline assessment of physical and cognitive function  
During this initial in-person visit, subjects read and sign an informed consent 
form approved by the IRB as well as answer questions pertaining to demographics and 
timing/dosage of medications. Potential subjects are required to describe in their own 
words the purpose and risks of the study in order to be eligible. Subjects will complete 
the MMSE to ensure sufficient mental capacity to understand the study procedures and 
follow instructions. (Mungas, 1991). A score of less than 22 will exclude a subject from 
continuing with the study. Blood pressure, height, and body mass are measured.   
Other baseline measures include PD assessments, mobility, and cognitive exams. 
Severity of PD is measured through the validated Movement Disorder Society revised 
United Parkinson’s Disease Rating Scale (MDS-UPDRS) (Goetz et al., 2007). Mobility is 
tested through the Timed Up-and-Go (TUG) test, which comprises standing from a chair, 
walking three meters, turning around a cone and returning to a seated position in the chair 
(Podsiadlo & Richardson, 1991). Cognition is assessed through a 30-minute 
computerized neuropsychological test battery (Mindstreams, NeuroTrax Corp., NJ) 
(Doniger, Simon, & Zivotofsky, 2006). The computerized cognitive assessment, 
NeuroTrax, assesses different cognitive domains including memory, attention, executive 
function, visual spatial processing and a global cognitive composite. The battery includes 
tests such as 1) “Go-NoGo” which tests response inhibition (Fig 2a), 2) Stroop which 
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tests a subject’s ability to switch his or her mindset to changing demands, 3) Catch Game 
to test motor related thinking, 4) finger-tapping to test motor skills (Fig 2b), 5) non-
verbal memory (immediate and delayed) by asking the subject to remember a shapes 
particular orientation (Fig 2c), 6) information processing by asking different levels of 
arithmetic problems varying from one to three numbers, and 7) problem solving by 
completing a pattern from a set number of choices (Fig 2d). Scores are age- and 
education-adjusted composite indices of each cognitive domain on an IQ-like scale, with 
the score of 130 representing the estimated population mean normalized for age and 
education level. This battery has been validated in elderly adults with and without a 
history of falls, patients with mild cognitive impairment, and patients with PD, and has 
shown to be useful in predicting falls and is responsive to therapeutic intervention (Ben-
Itzhak, Giladi, Gruendlinger, & Hausdorff, 2008, p. -; Doniger et al., 2005; Giladi et al., 
2006; Hausdorff et al., 2006; Mamikonyan, Xie, Melvin, & Weintraub, 2015; Paleacu et 
al., 2007). 
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A dual task assessment and a FOG provoking protocol are also completed at visit 
1 (and repeated at visits 2-4, see following section). Mobility data will be collected by 
instrumenting subjects with six small, wireless movement sensors (Mobility Lab®, 
APDM Inc., Seattle WA) that each contain a three-dimensional accelerometer and 
goniometer. These sensors are secured to the sternum, waist, wrists and ankles using 
Figure 2. Neurotrax Cognitive Assessment tests. (a) Go-NoGo: tests simple 
reaction time and response inhibition. The participant must quickly press the 
mouse button if the square is any color but red. (b) Finger Tapping: tests motor 
dysfunction by asking the participant to tap the mouse button as many times as 
possible while the rectangle fills red. (c) Non-verbal memory: measures immediate 
and delayed recognition memory by asking participants to remember 8 geometric 
patterns. A screen is the presented with 4 alternatives figures that the participant 
must identify as being on the previous page. (d) Problem solving: tests executive 
functioning and abstract reasoning as participants are asked to complete the 
pattern. 
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elastic straps. A dual-task paradigm was created to assess the ability to balance cognition 
and mobility. Subjects complete trials of walking back and forth along a 20m hallway in 
each of the following conditions: 
1) A “single task” condition, during which subjects will walk quietly at their 
preferred normal walking speed. 
2) A “dual task” trial, during which subjects are asked to walk at their preferred 
speed, while at the same time performing a cognitive task. The cognitive task 
consisted of verbalized, serial subtractions of 3 from a random, 3-digit number 
between 200-999. The starting number for each trial will be randomized to 
minimize practice-induced learning.  
The FOG provoking protocol is conducted, as proposed by Ziegler et al (2010). This 
protocol has been previously used in numerous studies (Herman, Rosenberg-Katz, Jacob, 
Giladi, & Hausdorff, 2014; Vandenbossche et al., 2012; Weiss, Herman, Giladi, & 
Hausdorff, 2015). This protocol takes less than five minutes to complete and includes 
situations that have been shown to provoke FOG. Patients are asked to sit, to stand up and 
to walk to a mark on the floor. They then perform two 360° turns, clockwise and counter-
clockwise. Then, the patients are asked to open a door and walk through it, turn outside, 
and come back to their chair. The subject does this under three different conditions: 
normal walk (NW) quietly, a motor task (MT) where the subject completes the course 
while holding a clear tray with a clear bottle of liquid, as well as a combined MT plus 
cognitive task (CT) where the subject is asked to continuously serial subtract 7s from a 
randomized number while also walking and carrying the tray. 
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Visits 2-4 (V2-V4): The effects of tDCS on walking 
 The effects of tDCS are tested by having subjects complete multiple tests both 
immediately before and after a 20-minute session of real or sham tDCS. Each of these 
visits last about 90 minutes and consists of the FOG protocol, the dual task paradigm 
(both described above), and a paper Stroop test. The Neurotrax computer assessment of 
V1 uses the same task and both forms of the Stroop test are meant to test executive 
function. This paper test takes 3-4 minutes to complete and includes three different tasks 
where the participant must read out loud from a list of words, as rapidly as possible, for 
45 seconds. During the word task (W), the participant reads words printed in black ink. In 
the color task (C), he/she reads the words printed in colored ink (red, green, and blue) 
which are mixed in with grey words. In the word-color task (WC), he/she is asked to read 
the colors of the printed words. These assessments are administered immediately before 
and after a single, 20-minute session of stimulation. For this test, higher scores indicate 
more words completed correctly in 45 seconds and thus, better performance.   
Each subject completes three tDCS visits in order to test the effects of the two 
different “real” tDCS conditions, as well as a sham condition (i.e. control or placebo). 
The study is double-blinded, such that the subjects are unaware of the specific condition, 
which are completed in random order. The following two “real” tDCS conditions will be 
tested: 
 
1. Unilateral motor stimulation: tDCS was delivered to facilitate neuronal 
excitability within the primary motor cortex (M1) of the hemisphere contralateral 
to the more affected side of the body, as determined by the motor subcomponent 
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of the UPDRS scale. This target region has been selected based on previous 
research demonstrating that tDCS targeting this brain region significantly reduces 
the frequency and severity of FOG episodes (Valentino et al., 2014). 
2. Unilateral motor and cognitive stimulation: tDCS will be delivered to 
simultaneously facilitate excitability within 1) the M1 region, and 2) the 
dorsolateral prefrontal cortex (DLPFC), of the contralateral hemisphere to the 
more affected side of the body, as determined by the motor subcomponent of the 
UPDRS scale. Simultaneous stimulation of these regions was chosen based on the 
aforementioned study by Benninger et al (2010),  as well as studies by Manor et al 
(2014,2015), which demonstrated that facilitation of the DLPFC significant 
improves locomotor control in healthy younger and older adults. If both sides of 
the body are similarly affected, the left hemisphere will be targeted.    
	17 
 
 
 
Study personnel certified by the Berenson-Allen Center for Noninvasive Brain 
Stimulation (BIDMC) in the administration of tDCS oversee the stimulation. Current is 
delivered with the Neuroelectrics Starstim device (Barcelona, Spain). A blinding scheme 
Figure 3. Electric field (V/m). The above images depict the electric fields in each 
set up of the 2 real montages. The red indicates a more positive charge (V/m) and 
the blue a more negative charge (V/m). The circles indicate electrode placement. 
The left is motor stimulation condition and the right the multifocal condition	
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was developed so that neither the participant nor study personnel knows which tDCS 
condition is delivered.  
The Starstim device is connected to six gel electrodes positioned on the scalp and 
held in place with a Neoprene cap. Prior to stimulation, subjects undergo a short session 
to determine the max level of intensity they are able to receive comfortably. To ensure 
subject safety, the total amount of injected current was limited to 4mA, while the 
maximum current intensity delivered by any single electrode was limited to 2mA 
(Brunoni et al., 2012). For each of the two “real” tDCS conditions, 20 minutes of 
continuous anodal stimulation is delivered. At the beginning of each session, stimulation 
automatically “ramps-up” in 0.1 mA increments over a 60sec period. Current 
automatically ramped down over the final minute of the session. For sham tDCS, the 
same electrode montage and session duration is used and current targeted both the 
DLPFC and M1 region simultaneously. However, current automatically ramps down to 
zero after the first minute of stimulation. This is a reliable control as sensations arising 
from tDCS diminish considerably after the first minute of stimulation (Gandiga, Hummel, 
& Cohen, 2006). At the end of each visit, subjects complete a short questionnaire 
(Brunoni et al., 2012) to assess potential side-effects. They are also asked to state if, in 
their opinion, they received real or sham stimulation on that day. They are then asked to 
rate on a 10 point scale how confident they are that they received that type of stimulation, 
with “1” being not confident and “10” being extremely confident. 
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Data Analysis 
As data collection is ongoing and the study is blinded, the final study analysis has 
yet to be completed. For the purpose of this thesis, we have focused on the results of the 
first subject as a case study. When the project is complete, the following measures will be 
analyzed:  
The primary outcome will be the dual task cost to walking speed. The dual task 
cost will be quantified by the percent change in walking speed between single- and dual-
task conditions. Secondary outcomes will include Stroop test performance as well as 
number and average duration of FOG episodes invoked by the FOG protocol. Additional 
temporospatial characteristics of single- and dual task-walking will also be computed 
from data collected by the Mobility Lab motion sensors. These measures will include 
stride time variability and the percent of each walking stride spent in double support (i.e., 
with both feet on the ground).  “Adjuster” variables will include age, baseline severity of 
PD as indicated by the MDS-UPDRS score, baseline mobility (i.e., TUG time), baseline 
cognitive performance as indicated by the computer-based testing battery, and serial 
subtraction performance during the dual task walking condition.  
 
Sample Size Determination 
In 37 healthy older adults, the pre-tDCS dual task cost to gait speed was 
approximately 0.1 m/s (Manor et al., 2015), a highly clinically-significant decrement, 
equivalent to an approximate 17% cost on average. Assuming a type-I error probability of 
0.05 and a standard deviation of within-subject change in cost as high as 5%, a sample of 
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10 will provide 90% power to detect a true cost reduction attributable to real tDCS, as 
compared to sham, as small as 6%. To account for the potential for greater heterogeneity 
of tDCS effects in PD patients as compared to healthy older adults, and to enable 
analyses of secondary outcomes, we propose to complete all study procedures in 15 
subjects.   
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RESULTS 
Case-study	
	
Participant 1 (initials JM) scored a 29 on the MMSE and was deemed cognitively 
able to understand the study and therefore eligible to participate. Overall JM scored a 
global cognitive score of 88.7 out of 130 on the Neurotrax cognitive assessment. The 
participant was below average (in comparison to age and education level) for the global 
cognitive score. In individual domains, JM was below average in attention, information 
processing speed, and more than 1 standard deviation below average in the memory 
domain. Scores were above average in executive function and motor skills. JM’s scores 
are shown in figure 4. 
 
 
 
 
Early onset PD was diagnosed about a year ago at the age of 42 with symptoms 
initially appearing on the left side. Symptoms have since progressed bilaterally. Although 
Figure 4. Neurotrax cognitive exam scores for case-study participant. JM scored a 
40.4 in the tasks that tested memory (below average), 103.5 in the executive function 
tasks (above average), 97 on the attention tasks (below average), 96.5 on the 
information processing tasks (below average), and 106.2 on the motor skill tasks 
(above average). 
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JM indicated having FOG through the NFOGQ during the phone screen, no FOG was 
observed in person and reported difficulties were primarily limited to rigidity. The 
participant initially earned a NFOGQ score of 15 out of a possible 33 during the phone 
screen; however, once shown a video for FOG at the visit 1 the participant indicated that 
this was not the symptom he experiences. No festination, FOG, or shuffling was observed 
during the Ziegler protocol across all visits. No PD medications have been prescribed and 
this person earned a score of 32.5 on the motor portion (part III) of the MDS-UPDRS and 
a Hoehn and Yahr scale score of 1.5, which signifies symptom severity in between 
unilateral (1) and bilateral involvement (2) without impairment of balance. 
 
tDCS efficacy and blinding 
     One primary purpose for this case study was to gauge the practicality and feasibility of 
tDCS as a therapeutic option within the PD population. The participants’ well-being was 
carefully monitored and their tolerance level of the stimulation was noted. Moreover, 
from a research standpoint, it is vitally important that the sham condition feels similar in 
comparison to the real tDCS conditions (i.e., motor and motor/DLPFC) to enable 
blinding, so that participants do not act based on pre-conception (i.e., the placebo effect). 
To observe side effects and blinding efficacy the participant answered if they experienced 
any side effects at each stimulation visit (Table 2). JM received the maximum allowable 
level of tDCS current during all visits. They did not experience any significant side 
effects, except after receiving the M1 stimulation, where they experienced mild redness 
of the skin and sleepiness. The participant claimed that the sleepiness was due to sitting 
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quietly for 20 minutes and not because of the stimulation itself. JM believed with high 
confidence that the first two sessions of stimulation were placebo and that the last session 
was the only real stimulation session. 
 
 
 
 
 
       Questions V2 (Real) V3 (Sham) V4 (Multi-focal) 
Headache Absent Absent Absent 
Neck pain Absent Absent Absent 
Scalp pain Absent Absent  Absent  
Sensations under the 
electrode (tingling, 
itching, burning, pain) 
Absent Absent Absent 
Skin redness Mild Absent Absent 
Sleepiness Mild Absent Absent 
Trouble Concentrating Absent Absent Absent 
Acute mood change Absent Absent Absent 
Others Absent Absent Absent 
Table 2: tDCS side effects. The following questions were asked posted stimulation 
during visits 2-4 to observe any adverse effects due to the stimulation. 
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The effects of tDCS on cognitive and motor outcomes 
For the purpose of reporting this participant as a case study, investigators were 
unblinded to tDCS condition and the participant’s dataset will not be included in the 
overall pilot study. During the first stimulation visit, JM received tDCS targeting the M1 
region. They received sham stimulation on their second visit, and multifocal tDCS 
targeting the both the M1 and DLPFC on the third visit.   
As compared to pre-tDCS assessments, JM’s performance did not exhibit 
definitive improvement across any of the particular Stroop tasks of cognitive function. 
Specifically, JM scored slightly lower (less words correct) across all three tasks of the 
Stroop test following motor stimulation (Fig 5a). Following sham stimulation, JM 
decreased his score in the W task, increase his score in the C task, and matched his pre-
Questions V2 
(Real) 
PS 
V2 
(Real) 
PP 
V3 
(Sham) 
PS 
V3 
(sham) 
PP 
V4 
(Real) 
PS 
V4 
(Real) 
PP 
Received real tDCS 
or the placebo today? 
Post-stimulation (PS) 
Post-performance (PP) 
Placebo Placebo Placebo Placebo Real Real 
Confidence: 1 being 
not and 10 being 
extremely confident? 
8 10 10 10 10 10 
Table 3: Blinding efficacy. The following questions were asked posted stimulation as 
well as at the end of the entire visit/post-performance to determine how predictable 
which stimulation montage the participant received that day.  
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stimulation score on the WC task (Fig 5b). JM reported with full confidence that the last 
stimulation was the real condition. Their scores in both the W and C tasks increased, but 
their score on the WC task decreased (Fig 5c).  
        
  
 
0	20	
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80	100	
120	
Pre-stimulation	 Post-stimulation	
a.	V2	(motor)		Stroop		scores	
W	 C	 WC	
0	20	
40	60	
80	100	
120	
Pre-stimulation	 Post-stimulation	
b.	V3	(sham)		Stoop	scores	
W	 C	 WC	
0	20	
40	60	
80	100	
Pre-stimulation	 Post-stimulation	
c.	V4	(multifocal)		Stroop	scores	
W	 C	 WC	
Figure 5. The effects of tDCS on Stroop test performance– The following scores 
are for the Stroop test, which assesses executive function. The blue (W) line was for 
the word task, the red (C) line for color task, and the green (WC) line for the word 
color-task. (a) Following M1 stimulation, the participant decreased performance 
across all three tasks. (b) Following sham stimulation, the participant increased 
performance in W, decreased in C, and remained the same for WC. (c) Following 
multifocal stimulation, the participant increased the score in W and C but decreased 
in WC. 
	26 
          The effects of tDCS on FOG were unable to be examined, as the participant did not 
exhibit any freezing episodes in the FOG-provoking task (i.e., the Ziegler protocol) or 
any of the gait assessments.   
 Unfortunately, the MobilityLab® sensors lost synchronization while tracking 
mobility and stride length and mean speed were not captured post-stimulation for visit 2. 
Sensors were in the process of being repaired when this participant completed visits 3 and 
4 so no MobilityLab data was collected during V3-4. In the case that mobility lab sensors 
were not working, the participant was timed with a stopwatch when completing the tasks.  
 Locomotor measures were collected prior to and post M1 stimulation. The data 
collected were used to create charts such as the one below (Fig 6) to calculate measures 
including mean stride length in meters (m) which is defined as the distance between two 
successive placements of one foot while walking, mean speed defined as meters/second 
(m/s), cadence (steps/minute), and mean cycle time defined in seconds (s) which is the 
time it takes for one foot to make two successive placements. Double support time was 
also recorded. As a participant completes each task, they move through multiple gait 
cycles where their feet alternate between being both on the ground (double support) 
versus one foot as they take a step (single support). Double support occurs twice in one 
gait cycle, while single support occurs once. Data recorded using MobilityLab at visit 2 
(Table 4) allowed the calculation of dual task costs and demonstrates the percent change 
from single to dual task (Table 5).  
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Figure 6. Accelerometer and gyroscope measurements.  By recording the time it 
takes for the participant to complete the task as well as when each foot strikes the 
ground, values such at mean cycle time can be calculated. These are the values from 
the sensor placed on the left foot, so each blue peak of the accelerometer is an 
indication of when the left foot strikes the ground. The long green vertical bars 
indicate when the participant reached the 20m mark and turned around (3 turns). Data 
presented were recorded during the normal walk task post M1 stimulation.  
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 On each stimulation visit, the participant completed two walking conditions prior 
to and post tDCS. As expected, prior to stimulation, performing serial subtractions (SB3) 
while walking caused a decrease in mean stride length (m), mean speed (m/s), and 
cadence (steps/minute), along with an increase in mean cycle time (s) and time spent in 
double support (% of gait cycle time). This indicates that given a dual task, JM took 
fewer, shorter steps and slowed down his speed. Following tDCS, performing SB3 also 
decreased cadence and double support time and increased gait cycle time (data was not 
collected for mean stride length or mean speed). By comparing pre-stimulation and post-
stimulation it can be observed that for the SB3 task, JM had lower cadence post 
stimulation and required less steps per minute to complete the task in comparison to pre-
stimulation. Post-stimulation, mean cycle time (s) and double support time increased in 
comparison to pre-stimulation and JM spent a longer time in double support as well as for 
an entire gait cycle.  
Variable Pre-stimulation Post-stimulation 
NW SB3 NW SB3 
Mean stride length (m) 1.63 1.58 N/A N/A 
Mean speed (m/s)  1.46 1.25 N/A N/A 
Mean cycle time (s) 1.11 1.27 1.24 1.63 
Cadence (steps/minute) 107.94 94.62 96.87 74.12 
Table 4: MobilityLab measurements. Mobility Lab sensors captured information on 
the movement of a participant’s legs as well as the lumbar region of their back. The 
following variables were calculated from these measurements.   
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The dual task cost to each walking metric was calculated as the percent change from the 
NW condition to the SB3 condition. This calculation was performed separately on pre- 
and post-tDCS trials. The dual task costs to mean cycle time significantly increased from 
-14.12% at baseline to -31.17% post tDCS. The dual-task cost also increased for cadence, 
which was 12.34% at baseline but 23.48% post tDCS (Table 5).   
Double support (% mean 
cycle time)  
21.46 	 26.00 24.59 28.71 
Dual task cost (%) Pre-Stimulation Post-Stimulation 
Mean stride length  +2.84% N/A 
Mean speed  +14.76% N/A 
Mean cycle time  -14.12% -31.17% 
Cadence  +12.34% +23.48% 
Double support   -3.74% -3.31% 
Table 5: Dual task cost. Dual task cost, or the percent change in each walking metric 
from single to dual task conditions, was calculated for each variable (mean stride 
length, mean speed, mean cycle time, cadence, and double support). A positive 
percentage shows an increase, where as a negative shows a decrease.    
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DISCUSSION 
Case-study findings 
 The results of this case-study indicate that tDCS did not have a significant effect 
on locomotion or cognitive function. However, the results do suggest that tDCS is 
feasible within the PD population, and that the sham stimulation condition is a largely 
valid control. The participant strongly believed that two of the three stimulation sessions 
were placebo, even though one of the supposed sham conditions was in fact real tDCS 
targeting the M1 region. When first asked whether they believed they received real or 
sham stimulation in this tDCS condition, the participant was less confident (8/10, refer to 
Table 2) in comparison to when asked post performance as well as the following visit 
(10/10). This indicates that the sham condition has a comparable sensation to the M1 
stimulation, in that the participant was unable to distinguish the two from each other. In 
other words, blinding was largely successful. Moreover, the participant did not report any 
discomfort and tolerated all tDCS conditions. 
 When healthy older adults walk, their speed, cadence, and stride length all 
significantly decrease when asked to perform a dual task. Moreover, as compared to 
walking normally, walking while pronouncing alternate letters of the alphabet from a 
randomly selected letter resulted in increased time spent in double support (Pilgram, 
Earhart, & Pickett, 2016; Simoni et al., 2013). In the present study, JM exhibited a 
similar pattern when assigned the serial subtractions dual task when walking. In studies 
investigating stance and swing times, PD participants were found to have an increased 
percentage of time spent in double support in comparison to healthy controls and that 
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freezers spent more time in this phase than non-freezers during dual-tasks (Vervoort et al., 
2016). It is thus possible that as JM’s PD progresses, these measures will be more 
severely impacted by the disease, especially if this participant begins to experience FOG.  
As expected, data collected from the current case study did not provide enough 
evidence to either support or refute the hypothesis of the study. As this study continues, 
more data will be collected to statistically examine the effects of tDCS on primary and 
secondary outcomes and thus evaluate the efficacy of this therapeutic strategy within the 
PD. With the one participant who has completed the study, the protocol was feasible and 
presented data will assist in the construction of a larger randomized control trial.    
 
Possibilities of ineffectiveness of tDCS in case study  
 There are multiple potential reasons as to why the results collected did not show 
an increase in the ability to dual-task or alleviate freezing of gait.  tDCS is a new 
technology still undergoing research as a form of therapy for a variety of disorders. As 
such, the most effective protocol (i.e., electrode placement, current intensity, stimulation 
duration, etc.) may not have yet been established. Moreover, several studies have tested 
the effects of tDCS over two-week periods as compared to a single session. In a 
previously mentioned study, Benninger and colleagues gave eight stimulation sessions 
that alternated between the M1 cortex and the DLPFC and demonstrated both an acute 
change in walking time (decrease post stimulation when on medication) as well as a long-
lasting improvement of bradykinesia (Benninger et al., 2010). A separate study examined 
the effects of tDCS stimulation targeting the DLPFC with current intensities of both 1mA 
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and 2mA and reported that the greater intensity improved working memory to a greater 
extent in PD patients (Boggio et al., 2006)  It is thus possible that the data did not show 
conclusive results because a single session of stimulation to these specific areas was not 
enough stimuli to induce change in investigated study outcomes.  
The observed inconclusive results may have also resulted from targeting sub-
optimal regions of the brain. Indeed, the complexity of the brain makes it difficult to 
pinpoint the exact location for the most beneficial stimulation target. Distributed parts of 
the brain work together as networks to perform a given function and exciting each 
individual section would be nearly impossible. In the case of dual tasking, multiple brain 
areas are at play. The bottleneck effect (refer to table 1) can occur in different areas: 
perception involves areas such as the bilateral intraparietal sulcus and in response 
selection, the bilateral premotor area, left inferior frontal gyrus, and pre-SMA (Marois, 
Larson, Chun, & Shima, 2006).  This study chose to stimulate the DLPFC and the motor 
cortex, but there is potential that anodal or cathodal stimulation would induce greater 
benefit in different regions such as those mentioned above. In addition to the vast number 
of options of regions to stimulate, restricting the current from reaching undesirable 
locations is also difficult to control. Hair acts as an insulator, so in this particular study 
the use of gel was used to reduce resistivity and allow the current more easily access the 
scalp. Bridging can occur, however, when excess gel leads to the possibility of the gel 
reaching other areas that were not initially planned to target (Horvath, Carter, & Forte, 
2014). 
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The stimulation of a given brain region may affect many different functions either 
directly or indirectly. In addition to the changes in dual tasking, executive function, and 
FOG, there is a possibility that each participant improved in a task not tested. By 
targeting the DLPFC and the motor cortex, the benefits may be seen in different aspects 
of the participants’ abilities. A flaw that comes with brain stimulation studies is the 
inability to investigate each and every function that ties to a particular brain region. For 
example, the DLPFC is also known for its role in executive functioning and each task 
requiring this type of brain activity may be affected to a different extent. For example, 
studies stimulating the DLPFC with tDCS in PD patients reported increased performance 
in working memory, in terms of both task accuracy and phonemic fluency task (Boggio et 
al., 2006; Pereira et al., 2013). Stimulating the DLPFC has also shown benefits in dual-
tasking and through the relationship between dual-tasking and FOG, it was proposed in 
this study that tDCS would then better freezing symptoms. As such, the chosen dual-task 
paradigm may not have been sensitive to the potential behavioral benefits induced by the 
tDCS intervention.   
 Another potential explanation as to why a significant difference was not seen pre- 
and post stimulation may be that the DLPFC is involved with an indirect route of 
processing that triggers FOG. Vandenbossche et. al proposed that the activation of the 
indirect route, which involves the prefrontal cortex, leads to a freezing episode as a result 
of increased cognitive demands (Vandenbossche et al., 2012). Measurements using 
functional infrared spectroscopy (fNIRS) supported this notion through a study 
measuring the blood perfusion of Brodmann 10, an area associated with executive 
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function. The results showed increased perfusion right before and also during a FOG 
episode (Fig 7) (Maidan et al., 2015). The DLPFC is located in Brodmann 46, which is 
located right behind Brodmann 10. In the future, studies should investigate the role of the 
anterior brain region more closely in FOG and determine if the stimulation of the DLPFC 
is beneficial to lessening FOG episodes.  
            
Figure 7: Blood Perfusion through Brodmann 10 during FOG. The red line indicates 
an increased activation of Brodmann area 10, reflecting an increase in oxygenated 
hemoglobin concentration, immediately prior to and during freezing of gait episodes in 
PD patients. The green line and blue line represent the level of perfusion when freezing 
did not occur during trials of normal walking and turning, respectively. Figure taken from 
(Maidan et al., 2015). 
  
Inter-subject variability may also be at play. Parkinson’s disease symptoms vary 
at different stages and some participants have more progressed symptoms versus the 
others. This may be subject to either a decreased chance or even more room for 
improvement. Freezing of gait is typically a symptom that appears much later in disease 
progression along with more severe symptoms and may not be seen in early age 
diagnoses (Spildooren et al., 2010) . The subject who completed the protocol at the 
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Hebrew Senior Life location was diagnosed relatively young at 40 years old, about two 
years ago. JM is relatively high functioning– a score of 29 on the MMSE places JM in the 
“normal” range and detects little to no cognitive impairment. The motor portion of the 
Neurotrax computer assessment scored JM as above average. As such, beneficial effects 
of tDCS may still be observed in the larger pilot study, as the average subject is expected 
to have a longer duration of PD progression and more severe symptoms.  
 A significant placebo-effect has been commonly observed in the PD population. 
In a literature review, a statistically significant difference was found in the efficacy of the 
placebo and that of the active drug in 61% of participants. In a literature search 
investigating the PD response to anti-oxidative treatment, out of the 198 placebo 
participants, 140 of them reported having a response to the medication (Shetty, Friedman, 
Kieburtz, Marshall, & Oakes, 1999). It has been hypothesized that this placebo effect is 
likely due to an activation of the damaged dopamine pathway. In PD, the degeneration of 
nerve cells that produce dopamine causes a reduced ability to begin or coordinate 
movements.  In fact, one study reported that placebo-induced improvements in PD 
symptoms were correlated with reduced binding of the dopamine competitor, 
[11C]raclopride (RAC) (Fuente-Fernández et al., 2001).  Neuroimaging studies have also 
found that placebos stimulate the release of dopamine in the striatum of PD patients and 
therefore, can affect their performance and related symptoms (Lidstone, 2014). This has 
led researchers to conclude that there is a higher placebo effect in Parkinson’s disease, 
since an expectation-induced neurochemical change may lead to the improvement of 
performance within particular tasks. It is thus crucial that a controlled sham condition is 
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monitored in order to determine what the potential cause of change in behavior is in 
result of. 
 A final mechanism that may have influenced results of the presented case study is 
the learning effect. In particular, the Stroop test was completed pre and post stimulation 
and a learning effect may have influenced performance. To minimize this effect, future 
research should include multiple versions of the Stroop test that each present the words in 
shuffled order. Since the same tests are repeated multiple times in visit 2-4, this change is 
likely to reduce the learning effect and yield better results.  
 
The potential of tDCS as a form of treatment 
 Although this one participant did not show significant improvement on any task, 
there is strong likelihood that others will receive greater benefit. The reasoning behind 
the effectiveness of brain stimulation is still in question (fig 8); however, there are 
multiple theories as to how tDCS works to improve mobility and cognition. Orban De 
Xivry and Shadmehr proposed three explanations of tDCS’s effect on motor control and 
learning: 1) the anodal stimulation increased neuronal firing rates while cathodal 
decreased them, 2) anodal stimulations strengthen newly formed associations, 3) the 
polarization caused by anodal stimulation modulates the memory of new or preferred 
firing patterns. By increasing firing rates and strengthening connections, the brain is 
better able to process and accomplish particular tasks (Orban de Xivry & Shadmehr, 
2014). This notion was also supported by a study that found tDCS modulates functional 
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connectivity of the cortico-striatal and thalamo-cortical circuits as well between each 
hemisphere in the human brain (Polanía, Nitsche, & Paulus, 2011). 
 
 
 Particularly in PD, it has been suggested that tDCS may play a role on protecting 
dopaminergic neurons and increasing dopamine levels. Due to the invasive procedures 
required to measure changes of dopamine in the brain, most of these studies are 
completed on animal models and have not yet been demonstrated in humans. In mice, 
anodal tDCS stimulation played a role reducing oxidative damage to dopaminergic 
neurons while cathodal stimulation to the frontal cortex found a significant increase of 
dopamine extracellularly (Lu et al., 2015; Tanaka, 2015). 
 By finding techniques in improving dual tasking, the overall lives of the elderly 
may be improved. With increased ability to dual task, executive function and attention 
may benefit and decrease the risk of falling. It has been found that those who have fallen 
Figure 8. The relationship between the potential benefits of tDCS treatment. 
This figure demonstrates the potential paths tDCS may take in improving brain 
function either for short term or long-term effects but shows the uncertainty 
between how they are connected. Taken from (Broeder et al., 2015). 	
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at least twice have scored less on cognitive exams in comparison to non-fallers 
(Hausdorff et al., 2006). The slower gait speed, shorter stride length, and increased 
double support time with dual tasking seen in JM as well as other studies in the elderly 
and PD, has been associated with an increased fear of falling (Verghese, Holtzer, Lipton, 
& Wang, 2009). The use of physical or cognitive training or technology such as tDCS 
can help improve the overall quality of life in the aging population 
 In summary, additional data will need to be collected for conclusive analysis of 
the effects of multi-focal tDCS on locomotor control and cognitive function within the 
PD population. Results from this case study nevertheless give us confidence that tDCS is 
tolerable for PD patients and that blinding to tDCS condition is feasible. No side effects 
of pain or significant discomforted were reported. Moreover, in-depth review of this 
participant’s data provided valuable information that will be used to optimize the 
efficiency of data collection procedures in future studies. The chief complaint from JM 
was the time it took to set up sensors and prepare the stimulation. Technical difficulties 
with MobilityLab sensors extended the time of JM’s visits.  In the future, the study team 
should thus implement additional ways to collect data such as an instrumented gait mat to 
more efficiently and effectively acquire mobility-related measures. Moreover, it is 
recommended that the study team expand the study inclusion criteria to also include those 
patients who received a PD diagnosis beyond ten years ago. FOG is typically a symptom 
that appears later with progression of the disease and as such, this change would allow 
study personnel to enroll participants who are more affected by Parkinsonian symptoms.  
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